Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST6GAL1 | P15907 | 9/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.38 |
| ▸ | CD22 | P20273 | 3/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13153381 | 1.00 | ST6GAL1 (0.41) | ST6GAL1P2RY2P2RY6CD22P2RY4 | |
| SCHEMBL2602690 | 0.96 | ST6GAL1 (0.40) | ST6GAL1P2RY2P2RY6CD22P2RY4 | |
| SCHEMBL18084277 | 0.96 | ST6GAL1 (0.39) | ST6GAL1P2RY2P2RY6CD22 | |
| SCHEMBL600526 | 0.90 | ST6GAL1 (0.44) | ST6GAL1 | |
| SCHEMBL16645359 | 0.88 | ST6GAL1 (0.44) | ST6GAL1P2RY2P2RY6CD22P2RY4 | |
| SCHEMBL17000271 | 0.87 | ST6GAL1 (0.43) | ST6GAL1P2RY2P2RY6CD22P2RY4 | |
| SCHEMBL18713167 | 0.87 | ST6GAL1 (0.43) | ST6GAL1P2RY2P2RY6CD22P2RY4 | |
| SCHEMBL18713166 | 0.87 | ST6GAL1 (0.43) | ST6GAL1P2RY2P2RY6CD22P2RY4 | |
| SCHEMBL10187590 | 0.86 | ST6GAL1 (0.45) | ST6GAL1P2RY2P2RY6CD22P2RY4 | |
| SCHEMBL20832018 | 0.86 | CD22 (0.43) | ST6GAL1P2RY2P2RY6CD22P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251409-A1 | Targeted Delivery of Factor VIII Proteins to Platelets | NOVO NORDISK AS (DK) | 2016-09-01 | — | — | US | disclosed |
| EP-2417155-B1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK AS (DK) | 2013-06-19 | — | — | EP | disclosed |
| EP-2417155-B1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK AS (DK) | 2013-06-19 | — | — | EP | disclosed |
| EP-2417155-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | Novo Nordisk A/S (DK) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115866-A1 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS | NOVO NORDISK A/S (DK) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251409-A1 | Targeted Delivery of Factor VIII Proteins to Platelets | F13B, F8, F13A1 | ST6GAL1 2265/4885P2RY2 3692/4885P2RY6 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.